Dermorphin

Dermorphin is a heptapeptide (7 amino acids) isolated from the skin of Phyllomedusa South American tree frogs. It is a potent and selective mu-opioid receptor (MOR) agonist, estimated to be 30–40 times more potent than morphine on a molar basis. A defining structural feature is the presence of a D-amino acid (D-alanine at position 2), which is exceptionally rare in naturally occurring vertebrate peptides and confers metabolic resistance and high receptor affinity. Dermorphin gained notoriety in horse racing doping scandals in 2012.

Dermorphin binds mu-opioid receptors with high affinity and selectivity, activating Gi/Go signaling to inhibit adenylyl cyclase, suppress voltage-gated calcium channels, and activate GIRK potassium channels. The result is profound neuronal inhibition in pain pathways including the dorsal horn and periaqueductal gray matter. The D-alanine residue at position 2 increases resistance to aminopeptidase cleavage, extending biological activity compared to endogenous opioid peptides. Dermorphin does not have meaningful affinity at delta or kappa opioid receptors at therapeutic concentrations.

Dermorphin's extreme potency and selectivity have made it a valuable pharmacological tool for opioid receptor characterization. Research applications include receptor binding studies, pain model experiments, and development of dermorphin-derived analogs with improved pharmacokinetics. Analogs such as DALDA (Tyr-D-Arg-Phe-Lys-NH2) and other modified sequences are studied for targeted analgesia. In 2012, dermorphin was detected in post-race urine samples of multiple racehorses at US tracks, leading to bans and prosecutions. No approved therapeutic applications exist for dermorphin in humans.